Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial

Harvey B DuBiner, Douglas A Hubatsch, Harvey B DuBiner, Douglas A Hubatsch

Abstract

Background: Medications to control intraocular pressure (IOP) are frequently preserved using benzalkonium chloride (BAK), which can negatively affect the ocular surface. Data are needed to assess efficacy and safety of prostaglandin drugs preserved with and without BAK. The present study compared the efficacy and safety of BAK-free travoprost 0.004% (TRAV) and BAK 0.02%-preserved bimatoprost 0.01% (BIM) during late-day time points in patients with open-angle glaucoma or ocular hypertension.

Methods: This was a 12-week, phase 4, randomized, investigator-masked, crossover study. 84 patients with IOP ≥24 and <36 mmHg were randomized 1:1 to receive once-daily TRAV or BIM for 6 weeks followed by an additional 6-week crossover period. IOP was measured at the end of each treatment period at 4, 6, and 8 pm. TRAV was considered noninferior to BIM if the upper limit of the 95% CI of the between-group difference in mean IOP was ≤1.5 mmHg. Adverse events were assessed throughout the study.

Results: One patient discontinued due to allergic conjunctivitis, and 2 patients with missing data were excluded; 81 patients were included in the per-protocol population (mean ± SD age, 58.3 ± 11.4 years; TRAV/BIM, n = 41; BIM/TRAV, n = 40). After 6 weeks, mean IOP with TRAV (17.4 ± 2.7 mmHg; change from baseline, -6.0 mmHg) was similar to BIM (17.2 ± 2.6 mmHg; change from baseline, -6.3 mmHg); the between-group difference was 0.22 mmHg (95% CI, -0.22 to 0.67). Thus, noninferiority of TRAV versus BIM was demonstrated. Mean IOP at each time point and mean and percentage IOP change from baseline were not significantly different between treatments. All treatment-emergent adverse events were mild to moderate. The incidences of mild ocular hyperemia with TRAV and BIM were 31% and 39%, respectively; moderate hyperemia was observed in 2% of patients receiving BIM.

Conclusion: Late-day IOP-lowering efficacy of BAK-free TRAV was noninferior to that of BAK 0.02%-preserved BIM; both reduced baseline IOP by 25%. Both treatments were well tolerated, although a higher incidence of moderate ocular hyperemia was observed with BIM.

Trial registration: ClinicalTrials.gov identifier, NCT01464424; registered November 1, 2011.

Figures

Figure 1
Figure 1
Patient flow. ITT = intent to treat; PP = per protocol.
Figure 2
Figure 2
Mean IOP at baseline and after 6 weeks of treatment with TRAV vs BIM. (a) Mean ± SD IOP across time points (i.e., mean of 4, 6, and 8 pm assessments). (b) Mean IOP at individual time points (TRAV, n = 80 at the 4 and 8 pm time points). BIM = bimatoprost 0.01%; IOP = intraocular pressure; TRAV = benzalkonium chloride–free travoprost 0.004%.

References

    1. American Academy of Ophthalmology Glaucoma Panel . Preferred Practice Pattern® Guidelines. Primary Open-Angle Glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2010.
    1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, II, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. doi: 10.1001/archopht.120.6.701.
    1. The Advanced Glaucoma Intervention Study (AGIS) Investigators The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440. doi: 10.1016/S0002-9394(00)00538-9.
    1. Collaborative Normal-Tension Glaucoma Study Group Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487–497. doi: 10.1016/S0002-9394(98)00223-2.
    1. Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12(3):232–236. doi: 10.1097/00061198-200306000-00009.
    1. McCarty CA, Mukesh BN, Kitchner TE, Hubbard WC, Wilke RA, Burmester JK, Patchett RB. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project. J Glaucoma. 2008;17(5):372–377. doi: 10.1097/IJG.0b013e31815c5f3f.
    1. Khaw PT, Shah P, Elkington AR. Glaucoma–2: treatment. BMJ. 2004;328(7432):156–158. doi: 10.1136/bmj.328.7432.156.
    1. Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:519–525.
    1. Toris CB, Zhan G, Fan S, Dickerson JE, Landry TA, Bergamini MV, Camras CB. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma. 2007;16(2):189–195. doi: 10.1097/IJG.0b013e31802fc6d3.
    1. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177–1185. doi: 10.1016/j.ophtha.2005.01.042.
    1. Aptel F, Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011;27(10):1949–1958. doi: 10.1185/03007995.2011.613923.
    1. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(suppl 1):S93–S105. doi: 10.1016/j.survophthal.2008.08.004.
    1. Inoue K, Shiokawa M, Higa R, Sugahara M, Soga T, Wakakura M, Tomita G. Adverse periocular reactions to five types of prostaglandin analogs. Eye (Lond) 2012;26(11):1465–1472. doi: 10.1038/eye.2012.195.
    1. Woodward DF, Phelps RL, Krauss AH, Weber A, Short B, Chen J, Liang Y, Wheeler LA. Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev. 2004;22(2):103–120. doi: 10.1111/j.1527-3466.2004.tb00134.x.
    1. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, Whitcup SM, Bimatoprost Study Group One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120(10):1286–1293. doi: 10.1001/archopht.120.10.1286.
    1. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49(suppl 1):S45–S52. doi: 10.1016/j.survophthal.2003.12.019.
    1. Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL, Bimatoprost Study G. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol. 2008;92(10):1387–1392. doi: 10.1136/bjo.2007.128454.
    1. Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010;149(4):661–671. doi: 10.1016/j.ajo.2009.12.003.
    1. Campbell JH, Schwartz G, Labounty B, Kowalski J, Patel VD. Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. Curr Med Res Opin. 2013;29(9):1201–1209. doi: 10.1185/03007995.2013.815160.
    1. Li N, Chen XM, Zhou Y, Wei ML, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol. 2006;34(8):755–764. doi: 10.1111/j.1442-9071.2006.01237.x.
    1. Hollo G, Vargha P, Kothy P. Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication. Curr Med Res Opin. 2005;21(12):1943–1948. doi: 10.1185/030079905X74916.
    1. Kaback M, Geanon J, Katz G, Ripkin D, Przydryga J, START Study Group Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Curr Med Res Opin. 2004;20(9):1341–1345. doi: 10.1185/030079904125004448.
    1. Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, Hua SY, Sullivan EK, Montgomery DB, Wells DT, Bergamini MV, Travoprost BAC-free Study Group Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16(1):98–103. doi: 10.1097/01.ijg.0000212274.50229.c6.
    1. Aihara M, Oshima H, Araie M, EXTraKT Study Group Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface – a multicentre randomized single-masked study. Acta Ophthalmol. 2013;91(1):e7–e14. doi: 10.1111/j.1755-3768.2012.02565.x.
    1. Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2(3):613–621.
    1. Miyashiro MJ, Lo SC, Stewart JA, Stewart WC. Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients. Clin Ophthalmol. 2010;4:1355–1359. doi: 10.2147/OPTH.S13460.
    1. Dubiner HB, Noecker R. Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004% Clin Ophthalmol. 2012;6:525–531. doi: 10.2147/OPTH.S30690.
    1. Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee CW, Kelly S, Mills E. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447–456.
    1. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418–423. doi: 10.1136/bjo.86.4.418.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj